Hospital
North Vista Hospital LLC
North Vista Hospital LLC was paid $31.56M by Medicaid between Jan 2018 and Dec 2024, across 228 billing codes. Its largest line is 99285, emergency room visit (most serious) — 18% of everything it billed.
33Billing provider infoNORTH VISTA HOSPITAL LLC
NORTH LAS VEGAS, NV 89030
NORTH LAS VEGAS, NV 89030
33aNPI1720037799assigned 05/08/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$31.56M
24GClaims1,572,158
24DCodes billed228
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Nevada
Rank by total paid#7 of 36
Median peer was paid$7.64M
This provider vs. median4.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DOAN, CHRISTOPHER controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 219,698 | $4.14M | |
| 2019 | 284,693 | $5.26M | |
| 2020 | 210,152 | $4.60M | |
| 2021 | 223,726 | $4.63M | |
| 2022 | 233,440 | $4.94M | |
| 2023 | 227,648 | $4.53M | |
| 2024incomplete | 172,801 | $3.46M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 18% | 48,873 | 41,508 | $5.72M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 62,901 | 54,711 | $4.73M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 82,475 | 69,978 | $3.98M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 5.5% | 12,331 | 10,833 | $1.74M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.3% | 4,572 | 4,027 | $1.05M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.3% | 38,585 | 32,448 | $1.04M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.7% | 13,385 | 11,663 | $838K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.8% | 3,913 | 3,289 | $554K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.6% | 27,009 | 23,499 | $519K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.6% | 1,943 | 1,676 | $516K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.6% | 8,944 | 8,152 | $513K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.6% | 12,153 | 9,974 | $502K |
216 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.5% | 25,710 | $480K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.4% | 40,139 | $453K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.4% | 3,059 | $431K |
| G0378 | Hospital observation service, per hour | 1.3% | 5,568 | $415K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 3,777 | $313K |
| 71045 | Radiologic examination, chest; single view | <1% | 43,408 | $301K |
| 80053 | Comprehensive metabolic panel | <1% | 67,268 | $301K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 23,200 | $289K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 21,003 | $266K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 78,419 | $259K |
| 70486 | <1% | 1,656 | $231K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 10,103 | $217K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 34,447 | $215K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 716 | $200K |
| 72131 | <1% | 1,357 | $187K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 36,401 | $156K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,285 | $154K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,198 | $150K |
| 73564 | <1% | 3,625 | $145K | |
| 90715 | <1% | 4,151 | $137K | |
| 0450 | Emergency room services | <1% | 3,169 | $130K |
| 83690 | <1% | 44,200 | $129K | |
| 81025 | <1% | 39,466 | $126K | |
| 84484 | <1% | 35,286 | $126K | |
| 73130 | <1% | 3,911 | $124K | |
| 76801 | <1% | 1,968 | $119K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,488 | $116K |
| 73630 | <1% | 3,718 | $113K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,454 | $108K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,462 | $108K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 18,345 | $106K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,802 | $104K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,809 | $104K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 25,008 | $96K |
| 36415 | Collection of venous blood by venipuncture | <1% | 86,719 | $90K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 5,444 | $88K |
| 83880 | <1% | 7,639 | $84K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 35,826 | $82K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,067 | $80K |
| 76830 | Ultrasound, transvaginal | <1% | 1,046 | $77K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,413 | $77K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 352 | $74K |
| 71250 | <1% | 886 | $69K | |
| 93971 | <1% | 1,581 | $67K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 7,106 | $67K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 749 | $66K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,510 | $65K |
| 73030 | <1% | 2,591 | $65K | |
| 87040 | <1% | 16,820 | $60K | |
| 73610 | <1% | 2,454 | $60K | |
| 73110 | <1% | 1,674 | $58K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,291 | $58K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 16,499 | $57K |
| 84702 | <1% | 7,769 | $55K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,180 | $53K |
| 81001 | <1% | 40,750 | $51K | |
| 93970 | <1% | 676 | $48K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,517 | $48K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 12,361 | $47K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 7,003 | $45K |
| 74018 | <1% | 2,918 | $40K | |
| 10060 | <1% | 573 | $39K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 647 | $38K |
| 94644 | <1% | 1,821 | $38K | |
| 83605 | <1% | 10,035 | $37K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 244 | $36K |
| 82550 | <1% | 14,470 | $36K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 6,250 | $36K |
| 29125 | <1% | 1,342 | $34K | |
| J3490 | Unclassified drugs | <1% | 9,117 | $33K |
| 87070 | <1% | 9,416 | $33K | |
| 72100 | <1% | 1,960 | $29K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 310 | $28K |
| 87186 | <1% | 7,826 | $28K | |
| 96376 | <1% | 3,834 | $26K | |
| 85730 | <1% | 13,281 | $26K | |
| 12001 | <1% | 810 | $26K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 23,018 | $24K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,748 | $23K |
| 87077 | <1% | 5,713 | $22K | |
| 70491 | <1% | 142 | $22K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 12,479 | $22K |
| 85610 | <1% | 16,325 | $21K | |
| 73080 | <1% | 907 | $21K | |
| 12002 | <1% | 524 | $20K | |
| 81003 | <1% | 23,348 | $19K | |
| 73590 | <1% | 709 | $19K | |
| 87420 | <1% | 2,375 | $17K | |
| 87088 | <1% | 4,387 | $16K | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 637 | $16K |
| 85379 | <1% | 3,696 | $15K | |
| 84145 | <1% | 1,534 | $14K | |
| 74022 | <1% | 526 | $14K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 535 | $14K |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 1,126 | $13K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 9,514 | $13K |
| 73502 | <1% | 889 | $13K | |
| 83735 | <1% | 5,901 | $12K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,214 | $12K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 12,693 | $11K |
| 84703 | <1% | 3,204 | $11K | |
| 85027 | <1% | 5,292 | $10K | |
| 94762 | <1% | 1,751 | $10K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,602 | $10K |
| 73090 | <1% | 408 | $9K | |
| 93017 | <1% | 707 | $9K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 2,708 | $8K |
| 12011 | <1% | 199 | $8K | |
| 71101 | <1% | 373 | $8K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 19,507 | $8K |
| 80076 | <1% | 2,944 | $8K | |
| 96367 | <1% | 720 | $8K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 8,295 | $7K |
| 72040 | <1% | 456 | $7K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 3,921 | $6K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 178 | $6K |
| 86901 | <1% | 4,611 | $6K | |
| 29515 | <1% | 175 | $6K | |
| 86900 | <1% | 4,610 | $6K | |
| 0270 | <1% | 378 | $6K | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 859 | $5K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 1,213 | $5K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 5,485 | $5K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,025 | $5K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 62 | $5K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 3,877 | $5K |
| 86140 | <1% | 2,547 | $5K | |
| 80061 | Lipid panel | <1% | 1,267 | $5K |
| 86703 | <1% | 839 | $5K | |
| 84439 | <1% | 1,445 | $5K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 6,208 | $4K |
| 82962 | <1% | 11,108 | $4K | |
| A4223 | Infusion supplies not used with external infusion pump, per cassette or bag (list drugs separately) | <1% | 95 | $4K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,037 | $4K |
| 96368 | <1% | 467 | $4K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 2,585 | $4K |
| 87299 | <1% | 640 | $4K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,128 | $4K |
| 87210 | <1% | 1,586 | $3K | |
| 0250 | <1% | 661 | $3K | |
| 64721 | <1% | 14 | $3K | |
| Z7502 | <1% | 84 | $3K | |
| 85007 | <1% | 2,692 | $3K | |
| 80329 | <1% | 544 | $3K | |
| J1815 | Injection, insulin, per 5 units | <1% | 4,171 | $3K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,725 | $3K |
| 76870 | <1% | 95 | $3K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,523 | $3K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,149 | $3K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,964 | $2K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,940 | $2K |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 598 | $2K |
| 87641 | <1% | 189 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 55 | $2K |
| 86803 | <1% | 251 | $2K | |
| 94645 | <1% | 132 | $2K | |
| 80074 | <1% | 102 | $2K | |
| 99070 | <1% | 354 | $2K | |
| 82010 | <1% | 427 | $1K | |
| 82947 | <1% | 1,919 | $1K | |
| 85651 | <1% | 937 | $1K | |
| 86850 | <1% | 1,179 | $1K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 306 | $1K |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 244 | $1K |
| 0272 | <1% | 216 | $1K | |
| 74230 | <1% | 31 | $980.66 | |
| J2212 | Injection, methylnaltrexone, 0.1 mg | <1% | 20 | $974.41 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 283 | $888.41 |
| 73140 | <1% | 27 | $734.48 | |
| 82805 | <1% | 76 | $674.99 | |
| 71111 | <1% | 31 | $531.96 | |
| 82728 | <1% | 138 | $524.27 | |
| 73562 | <1% | 16 | $511.35 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 210 | $496.21 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 151 | $485.05 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 400 | $471.78 |
| 86592 | <1% | 208 | $434.32 | |
| 72070 | <1% | 14 | $380.06 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 149 | $355.07 |
| 29130 | <1% | 15 | $324.33 | |
| 85652 | <1% | 266 | $304.27 | |
| 80320 | <1% | 5,240 | $299.73 | |
| A4208 | Syringe with needle, sterile 3 cc, each | <1% | 248 | $284.44 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 124 | $274.24 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 2,606 | $260.84 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 182 | $258.80 |
| 0271 | <1% | 33 | $251.46 | |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,671 | $247.45 |
| Z7610 | <1% | 27 | $244.31 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,051 | $238.23 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 46 | $222.08 |
| 84100 | <1% | 185 | $215.54 | |
| 82607 | <1% | 44 | $215.19 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 221 | $215.02 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 348 | $202.52 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 93 | $193.77 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 369 | $165.18 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 19 | $122.73 |
| 99406 | <1% | 43 | $122.54 | |
| A6449 | Light compression bandage, elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard | <1% | 133 | $110.49 |
| 90732 | <1% | 29 | $107.75 | |
| 90686 | <1% | 46 | $105.00 | |
| 88300 | <1% | 338 | $87.24 | |
| G0009 | Administration of pneumococcal vaccine | <1% | 15 | $66.40 |
| 87205 | <1% | 44 | $52.20 | |
| A4556 | Electrodes, (e.g., apnea monitor), per pair | <1% | 30 | $28.26 |
| A6255 | Specialty absorptive dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., with any size adhesive border, each dressing | <1% | 12 | $16.52 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 300 | $15.78 |
| 80069 | <1% | 29 | $5.87 | |
| A4206 | Syringe with needle, sterile, 1 cc or less, each | <1% | 17 | $5.85 |
| A4215 | Needle, sterile, any size, each | <1% | 27 | $5.14 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 22 | $3.03 |
| A6443 | Conforming bandage, non-elastic, knitted/woven, non-sterile, width greater than or equal to three inches and less than five inches, per yard | <1% | 15 | $2.56 |
| G0008 | Administration of influenza virus vaccine | 0% | 55 | $0.00 |
| Q4139 | Amniomatrix or biodmatrix, injectable, 1 cc | 0% | 18 | $0.00 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 83 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOAN, CHRISTOPHER (MANAGING ASSOCIATE GENERAL COUNSEL)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.